Objectives: In this study, we wanted to assess the level of antimicrobial resistance, the presence of genes encoding resistance to cephalosporins and plasmid-mediated quinolone resistance (PMQR), and genetic relatedness among Shigella isolates obtained from Iranian patients.
Introduction
Shigella is an important cause of acute diarrhoeal disease. Worldwide, there are 164.7 million cases yearly, and 1.1 million people are estimated to die from Shigella infections. 1 A total of 69% of all episodes and 61% of all deaths attributable to shigellosis involve children ,5 years of age. 1 In Iran, shigellosis is one of the major causes of childhood morbidity associated with diarrhoea. 2, 3 All four species of Shigella (Shigella dysenteriae, Shigella flexneri, Shigella boydii and Shigella sonnei) can cause shigellosis.
S. flexneri is endemic in many developing countries and causes higher mortality than other Shigella species. 4 The most common serotype is S. flexneri serotype 2a, but other serotypes are also of major importance. 1 In Iran, S. flexneri was the most frequent cause of shigellosis up to 2003, 5, 6 when a shift in highest prevalence towards S. sonnei was observed.
A range of antimicrobials is effective for the treatment of shigellosis, although the options have become limited due to the emergence of multidrug resistance. Thus, sulphonamides, tetracycline, ampicillin and co-trimoxazole are no longer recommended for empirical treatment. 7 An increase in the occurrence of antimicrobial resistance, including resistance to fluoroquinolones and third-and fourth-generation cephalosporins, among S. sonnei has been observed in several countries. 8 -15 To date, bla CTX-M-15 , bla CTX-M-14, bla CTX-M-3 and bla CMY-2 genes have been reported in S. sonnei isolates. A few articles have described the presence of plasmid-mediated quinolone resistance (PMQR) determinants mainly associated with S. flexneri, where the qnrS1 gene appears to be dominant. 16 -18 The emergence of antimicrobial resistance is a matter of concern 19 and poses major difficulties in the determination of appropriate antimicrobial treatment due to shifts in the prevalences of the different serogroups and changes in the resistance patterns. 7 Knowledge of the occurrence of different serotypes in different countries and geographic regions may assist in the recognition and tracing of emerging pathogens and in the implementation of correct treatment and control strategies. 1 In this study, we have determined the serotype distribution and antimicrobial resistance profiles as well as the genes conferring resistance to quinolones, extended-spectrum b-lactamase (ESBL) and AmpC b-lactam antimicrobials among Shigella spp. collected from patients admitted to Milad Hospital, Tehran, Iran, during 2008-10. Additionally, we have investigated the molecular relatedness of S. sonnei isolates using PFGE.
Materials and methods

Sample collection
A total of 848 patients admitted to Milad Hospital, Tehran, Iran, between September 2008 and March 2010 suffered from acute diarrhoea and gastroenteritis. Only patients without a history of antimicrobial consumption submitted stool samples and were included in the study. From the 848 patients, 44 Shigella isolates were obtained and further analysed.
The strains were isolated directly from fresh stool samples following plating on selective agar and biochemical testing. The selective agar plates [MacConkey agar, Salmonella-Shigella agar and XLD agar (Merck, Hamburg, Germany)] were incubated at 378C for 18 -24 h. Presumptive Shigella colonies were identified based on the following biochemical tests: triple sugar iron agar, motility-indole-urea agar and IMVIC (indole, methyl red, Voges-Proskauer and citrate). A subset of 37 viable isolates (the other 7 isolates did not survive storage) were included in this study and sent to the National Food Institute, Technical University of Denmark (DTU Food) for further analysis.
Serotyping
Presumptive Shigella isolates were sent to the WHO National Salmonella and Shigella Center, National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Bangkok, Thailand, and serotyped based on serological slide agglutination, using the polyvalent antisera A, A1, B, C, C1, C1-3 and D and the following monovalent antisera: S. dysenteriae type 1 -12; S. flexneri type I-VI and group factor (3)4, 6 and 7(8); S. boydii type 1 -18; and S. sonnei phase I -II (S & A Reagents Ltd, Bangkok, Thailand). The serotypes were interpreted according to the Manual of Clinical Microbiology. 20 
Antimicrobial susceptibility
MIC testing was performed at DTU Food using the following antimicrobials: ampicillin, amoxicillin/clavulanic acid, apramycin, cefotaxime, ceftiofur, chloramphenicol, ciprofloxacin, colistin, florfenicol, gentamicin, nalidixic acid, neomycin, spectinomycin, streptomycin, sulfamethoxazole, tetracycline and trimethoprim. For ESBL-producing and/or AmpC-blactamase-producing isolates, susceptibility to the following b-lactams was also tested: cefazolin, cefepime, cefoxitin, cefpodoxime, ceftazidime, ceftriaxone, cefalotin, imipenem and meropenem. Epidemiological cut-off values according to current EUCAST recommendations (http ://www.eucast.org) were applied, other than for amoxicillin/clavulanic acid, apramycin, ceftriaxone, cefazolin, cefepime, spectinomycin and sulfamethoxazole where CLSI standards and clinical breakpoints were used. 21 -23 As the quality control, E. coli ATCC 25922 was used according to the CLSI standards.
21,23
Detection of resistance genes
Of the 37 Shigella isolates, eight strains exhibiting resistance to ceftiofur and cefotaxime were examined for the presence of bla TEM , bla CTX , bla SHV , bla CMY-1 and bla CMY-2 as previously described. 24, 25 One isolate showing reduced susceptibility to ciprofloxacin and susceptibility to nalidixic acid was tested by PCR for the presence of PMQR genes [qnrA, qnrB, qnrC, qnrD, qnrS, qepA and aac(6 ′ )-lb] as previously described. 25 -27 PCR products were purified using a GFX TM PCR DNA Kit (GE Healthcare, Chalfont St Giles, UK) and submitted to Macrogen Inc. (Seoul, Korea) for sequencing. Sequence analysis and alignments were performed using Vector NTI suite 9 (InforMax Inc., Bethesda, MD, USA). The resulting nucleotide sequences were compared with sequences from public databases (www.ncbi.nlm.nih.gov and www.lahey.org/studies/).
PFGE
All 25 S. sonnei isolates were analysed for genetic relatedness by PFGE using XbaI (Fermentas, Glen Burnie, MD, USA) according to the US CDC PulseNet protocol. 28 Electrophoresis was performed with a CHEF-DR III System (Bio-Rad Laboratories, Hercules, CA, USA) using 1% SeaKem Gold agarose in 0.5× Tris/borate/EDTA at 6 V with an angle of 1208 (one phase 2.2-54.2 s, run time 20 h).
Results
Patient data
The age of infected patients ranged from 2 to 56 years (median 7 years). The ratio between genders was 1: 0.85 (females/males).
Serotyping
All four species of Shigella were represented among the 37 isolates. Of these, 25 (68%) were S. sonnei phase II, with 5 (14%) S. flexneri, 5 (14%) S. dysenteriae type 2, and 2 (5%) S. boydii type 2. In addition, three different serotypes of S. flexneri were detected: 2 (5%) type 1b (I: 4, 6), 1 (3%) type 2b (II: 7, 8), and 2 (5%) untypeable (Table 1) .
Antimicrobial resistance
All Shigella species showed multidrug resistance to at least three classes of antimicrobial agent. However, susceptibility to the different antimicrobials appeared to differ depending on the species and serotype ( Table 1 ). The 25 S. sonnei phase II isolates exhibited resistance to the highest number of antimicrobials, followed by S. flexneri type 1b. In general, these 27 isolates were resistant to 13 of the 17 antimicrobials tested, but differences between the isolates were observed. Resistance to streptomycin, sulfamethoxazole, tetracycline and trimethoprim was common Shigella infections from Iran for S. sonnei (96%-100%, n¼ 24), S. flexneri serotype 1b (100%, n¼ 2) and S. dysenteriae type 2 (100%, n¼5). In addition, 18 isolates (16 S. sonnei and 2 S. boydii type 2) exhibited resistance to nalidixic acid and low-level resistance to ciprofloxacin. In contrast, one isolate of S. flexneri serotype 1b exhibited low-level resistance to ciprofloxacin but was susceptible to nalidixic acid. Resistance to b-lactam antimicrobials ceftiofur, cefazolin, cefalotin, cefpodoxime, ceftriaxone and cefotaxime was observed in all six (24%) of the S. sonnei phase II isolates. Of these, five (83%) also exhibited resistance to ceftazidime and one (17%) also exhibited resistance to cefoxitin. In addition, the two S. flexneri type 1b isolates were resistant to b-lactam antimicrobials with the exception of cefoxitin. None of the strains was resistant to apramycin, carbapenems (imipenem and meropenem), colistin or florfenicol ( Table 1) .
Identification of genes conferring resistance to third-and fourth-generation cephalosporins and PMQR determinants
Among the six isolates of S. sonnei phase II resistant to thirdgeneration cephalosporins, five harboured bla CTX-M-15 and one harboured bla CMY-2 . The two S. flexneri type 1b were also positive for the presence of bla CTX-M-15 . Additionally, one of the S. flexneri type 1b that displayed the PMQR phenotype harboured a qnrS1 gene.
PFGE
A subset of 25 S. sonnei phase II isolates were subtyped by PFGE, and seven unique XbaI PFGE patterns were observed. The three XbaI PFGE clusters contained 15, 4 and 2 isolates, with distinct profiles (Figure 1 ). Within each of the clusters containing four or two isolates, the strains exhibited the same antimicrobial resistance profile (Figure 1) . Furthermore, in the main cluster, 10 of the 15 isolates displayed the same antimicrobial resistance profile. No correlation was detected between the PFGE profile and age or gender of the patient or time of infection.
Discussion
Over the past decade, an emergence of ESBL-producing Shigella spp. has been observed in the Middle East, South-East Asia, China and Argentina, where the presence of bla CTX-M-15 , bla CTX-M-14 and bla CTX-M-3 genes has been reported. 8 -15 However, worldwide only a few reports have described the presence of AmpC b-lactamases (bla CMY-2 ) and PMQR (qnrS1, qnrB6 and qnrB19) in Shigella spp. 16 -18,29,30 In 2010, the first characterization of ESBL-producing Salmonella enterica harbouring bla CTX-M-15, bla CTX-M-88 and bla TEM-169 from Iran was described. 31 This study reports the first known description of ESBL producers (harbouring bla CTX-M-15 ), AmpC b-lactamase producers (harbouring bla CMY-2 ) and PMQR (harbouring qnrS1) in S. sonnei phase II and S. flexneri serotype 1b isolated from patients in Iran. This is indeed a worrisome development in antimicrobial resistance, especially as the S. sonnei phase II isolates were highly resistant to many of the antimicrobials tested, including decreased susceptibility to ciprofloxacin, complicating the (68) 1 (4) 8 (32) 6 (24) 0 0 16 (64) 2 (8) 6 (24) 16 (64) 1 (4) 2 (8) 24 (96) 24 (96) 24 (96) 25 (100) S. flexneri type 1b 3 (8) 8 (22) 18 (49) 2 (5) 14 (38) 36 (97) 35 (95) 34 (92) 37 (100) AMC, amoxicillin/clavulanic acid; AMP, ampicillin; XNL, ceftiofur; CHL, chloramphenicol; CIP, ciprofloxacin; GEN, gentamicin; CTX, cefotaxime; NAL, nalidixic acid; NEO, neomycin; SPT, spectinomycin; STR, streptomycin; SMX, sulfamethoxazole; TET, tetracycline; TMP, trimethoprim. Tajbakhsh et al.
treatment of the patients. Interestingly, the patients selected for this study claimed not to have been subjected to any antimicrobial treatment prior to their hospitalization. This underlines the extensive selection pressure present in the Iranian community, where self-medication due to 'over the counter' antimicrobial consumption and abuse of prescribed antimicrobials is widespread. 32 Our results emphasize the need for prudent and controlled use of antimicrobials, especially third-generation cephalosporins and fluoroquinolones, in the treatment of invasive infections to avoid further acquisition of resistance to these antimicrobials, which have been designated by the WHO as critically important for human health. 33 The detection of ESBL producers, AmpC b-lactamase producers and PMQR in Shigella spp. for the first time in Iran (to our knowledge) was surprising and indicates a lack of data on the prevalence of these types of resistance genotype, and illustrates the need to establish a proper antimicrobial resistance surveillance system 34, 35 to monitor the emergence and development of antimicrobial resistance. Furthermore, it is important to initiate strategies for prevention and control, such as those mentioned by Niyogi 19 provision of safe and abundant water, effective faeces disposal, education on how to avoid faecal contamination of food and water, awareness programmes focusing on hand washing and breast feeding, promotion of oral rehydration therapy to patients suffering from acute diarrhoea and supply of additional nutrients to children recovering from acute diarrhoea or dysentery. 7, 36 A high genetic homogeneity was observed among S. sonnei phase II isolates, of which many clustered with similar antimicrobial susceptibility patterns. Based on the isolates in this study, it is uncertain whether this is the result of sporadic outbreaks or clonally related endemic isolates present in Iran. Limited PFGE data are available in Iran; however, Ranjbar et al. 37 suggested endemic circulation of S. sonnei in Tehran, Iran. Additionally, the PFGE profile of the main cluster seems to correspond to both the antimicrobial resistance pattern and PFGE profile of the second largest PFGE cluster obtained during the 18 years of antimicrobial resistance surveillance in Belgium. 36 The hypothesis of endemic circulation of S. sonnei cannot yet be confirmed due to the limited PFGE data available as well as the low discriminatory power of PFGE for Shigella spp. 38 Further studies aimed at understanding the clonal relatedness of S. sonnei strains need to be initiated in order to investigate the hypothesis raised in this study and by Ranjbar et al. 37 In conclusion, this study describes the presence of the first ESBL producers (bla CTX-M-15 ), AmpC b-lactamase producers Shigella infections from Iran (bla CMY-2 ) and PMQR (qnrS1) in S. sonnei and S. flexneri isolated from patients in Iran. Antimicrobial susceptibility testing revealed high levels of antimicrobial resistance in all Shigella species detected. Based on PFGE, a high genetic homogeneity was observed among S. sonnei phase II isolates, many of which clustered with similar antimicrobial susceptibility patterns. Additionally, this is the first known description of serotype distribution among Shigella spp. encountered in a hospital setting in Tehran, Iran, and it revealed that S. sonnei was by far the most common Shigella species, followed by S. flexneri and S. dysenteriae. Since there is a lack of data on the epidemiology of Shigella spp. in Iran, we encourage the Iranian authorities to establish a rigorous antimicrobial resistance surveillance system to monitor the emergence and development of antimicrobial resistance and to initiate strategies for prevention and control to reduce the burden of shigellosis in Iran.
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